Investigational drug · Phase 2
Pelareorep
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
35
Any phase or sponsor naming "Pelareorep"
First trial start
2020
Jun 10, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pelareorep", any sponsor or status.
Conditions studied
As listed on its trial records.
- Anal Cancer Metastatic
- Squamous Cell Carcinoma of the Anus Stage Unspecified
- Pancreatic Cancer Metastatic
- Unresectable Pancreatic Carcinoma
- Breast Cancer Metastatic
- Ras-mutated Metastatic Colorectal Cancer
- mCRC
- MSS Metastatic Colorectal Cancer
Approved drugs for the same conditions: Breast cancer · Colorectal cancer · Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Pelareorep" as an intervention, largest first.
- Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck CancersPivotal-lookingCompleted
Oncolytics BiotechIndustry
NCT01166542 · 167 participants · Start Jun 2010 · Primary completion Apr 2012
Drug: REOLYSIN; Carboplatin and 2 more · For: Carcinoma, Squamous Cell of the Head and Neck
Sites: Birmingham, Alabama; Tucson, Arizona; Burbank, California · 77 sites in all
- Reolysin in Previously Treated Advanced/Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage TherapyPivotal-lookingCompleted
Canadian Cancer Trials GroupResearch network
NCT01708993 · 166 participants · Start Dec 10, 2012 · Primary completion Jan 26, 2016
Drug: Pemetrexed and Reolysin (and safety run-in); Pemetrexed and 2 more · For: Non Small Cell Lung Cancer
Sites: Calgary, Canada; Abbotsford British Columbia, Canada; Surrey, Canada · 12 sites in all
- A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and AtezolizumabActive, not recruiting
Oncolytics BiotechIndustry
NCT07280377 · 122 participants (planned) · Start Oct 27, 2021 · Primary completion Jul 30, 2027
Drug: Pelareorep; Atezolizumab and 3 more · For: Anal Cancer Metastatic; Squamous Cell Carcinoma of the Anus Stage Unspecified; Pancreatic Cancer Metastatic and 1 more
Sites: Heidelberg, Germany; Heilbronn, Germany; Tübingen, Germany · 15 sites in all
- Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal CancerPivotal-lookingCompleted
Canadian Cancer Trials GroupResearch network
NCT01622543 · 109 participants · Start Oct 26, 2012 · Primary completion Jan 18, 2017
Drug: Folfox plus Bevacizumab and reolysin; Folfox plus Bevacizumab · For: Colorectal Cancer
Sites: Calgary, Canada; Vancouver, Canada; Hamilton, Canada · 10 sites in all
- Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT01199263 · 108 participants · Start Dec 6, 2010 · Primary completion Jun 1, 2015
Drug: Paclitaxel; Pelareorep · For: Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Sites: Burbank, California; Mountain View, California; Hartford, Connecticut · 36 sites in all
Canadian Cancer Trials GroupResearch network
NCT01619813 · 85 participants · Start Dec 14, 2012 · Primary completion Apr 26, 2016
Drug: Docetaxel, Reolysin and Prednisone; Docetaxel and Prednisone · For: Prostate Cancer
Sites: Calgary, Canada; Edmonton, Canada; Abbotsford British Columbia, Canada · 11 sites in all
Canadian Cancer Trials GroupResearch network
NCT01656538 · 81 participants · Start Feb 20, 2013 · Primary completion Nov 18, 2016
Drug: Paclitaxel; Reolysin · For: Metastatic Breast Cancer
Sites: Kelowna, Canada; Vancouver, Canada; Victoria, Canada · 7 sites in all
National Cancer Institute (NCI)NIH
NCT01280058 · 73 participants · Start Dec 2010 · Primary completion Jan 19, 2016
Drug: Carboplatin; Paclitaxel and 1 more · For: Pancreatic Acinar Cell Carcinoma; Pancreatic Ductal Adenocarcinoma; Recurrent Pancreatic Carcinoma and 1 more
Sites: Washington D.C., District of Columbia; Atlanta, Georgia; The Bronx, New York · 6 sites in all
National Cancer Institute (NCI)NIH
NCT00602277 · 70 participants · Start Apr 2008 · Primary completion Aug 2016
Drug: Wild-type Reovirus · For: Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal Carcinoma
Sites: Columbus, Ohio
Oncolytics BiotechIndustry
NCT07446322 · 60 participants (planned) · Start Apr 30, 2026 · Primary completion Aug 30, 2027
Drug: Bevacizumab; FOLFIRI and 1 more · For: Ras-mutated Metastatic Colorectal Cancer; mCRC; MSS Metastatic Colorectal Cancer
Sites: Homewood, Alabama; Beverly Hills, California; Encino, California · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Oncolytic viruses in cancer therapy: Mechanisms, challenges, and emerging clinical applications.
Jadhav SP, Patil CD, Pawar AY, et al. · Ann Pharm Fr 2026
- Identification of reovirus reassortants with enhanced oncolytic activity in human fibrosarcoma cells.
Dagli CV, Hutchinson JR, Efremov AK, et al. · Virus Genes 2026
- In Vivo Tracking Modalities for Oncolytic Reovirus: Principles, Clinical Applications, and Translational Integration.
Rastegarpanah M, Kafi ZZ, Negahdari B · Mol Imaging Biol 2026
- Operation oncolysis: Reoviruses in the theater of cancer war.
Voon K, Siew ZY · Adv Cancer Res 2026
- Oncolytic Viruses in Glioblastoma: Clinical Progress, Mechanistic Insights, and Future Therapeutic Directions.
Liu J, Wang Y, Su S, et al. · Cancers (Basel) 2025
- The Emerging Role of Oncolytic Virotherapy in Glioblastoma Management.
Nizamutdinov D, Sentmanat A, Tong J, et al. · Cancers (Basel) 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.